Literature DB >> 15285980

Sustained remission of schizophrenia among community-dwelling older outpatients.

Lisa A Auslander1, Dilip V Jeste.   

Abstract

OBJECTIVE: The frequency and nature of sustained remission of schizophrenia are controversial.
METHOD: The authors assessed the prevalence of sustained remission among 155 middle-aged and elderly outpatients living independently. They compared patients with sustained remission to symptomatic schizophrenia patients and normal comparison subjects using standardized psychopathological, cognitive, and functional measures.
RESULTS: Eight percent of the older schizophrenia patients living independently met criteria for sustained remission. Their level of psychopathology was similar to that in normal subjects and lower than that in symptomatic patients. On cognition, quality of well-being, and everyday functioning, the group with sustained remission was intermediate between the normal and symptomatic groups and differed significantly from the normal subjects.
CONCLUSIONS: Sustained remission can occur even in older patients with very chronic illness, but its prevalence is lower than that in several published reports. Remission may reflect a return to premorbid functioning, consistent with neurodevelopmental hypotheses of schizophrenia.

Entities:  

Mesh:

Year:  2004        PMID: 15285980     DOI: 10.1176/appi.ajp.161.8.1490

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Perspectives on schizophrenia over the lifespan: a qualitative study.

Authors:  Sally Shepherd; Colin A Depp; Gloria Harris; Maureen Halpain; Lawrence A Palinkas; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2010-07-05       Impact factor: 9.306

2.  Can medication-free research ever be ethical in older people with psychotic disorders?

Authors:  Dilip V Jeste
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

3.  Outcome among community dwelling older adults with schizophrenia: results using five conceptual models.

Authors:  Carl I Cohen; Richa Pathak; Paul M Ramirez; Ipsit Vahia
Journal:  Community Ment Health J       Date:  2008-09-12

4.  Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Authors:  D L Kelly; E Weiner; M P Ball; R P McMahon; W T Carpenter; R W Buchanan
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

5.  Relationship between incidence and prevalence in psychotic disorders: An incidence-prevalence-mortality model.

Authors:  Baptiste Pignon; Franck Schürhoff; Grégoire Baudin; Andrea Tortelli; Aziz Ferchiou; Ghassen Saba; Jean-Romain Richard; Antoine Pelissolo; Marion Leboyer; Andrei Szöke
Journal:  Int J Methods Psychiatr Res       Date:  2018-05-22       Impact factor: 4.035

Review 6.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

Review 7.  Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

Authors:  Dilip V Jeste; Owen M Wolkowitz; Barton W Palmer
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

8.  Positive light on schizophrenia and aging: Commentary on course and predictors of symptomatic remission in schizophrenia: A 5-year follow-up study in a Dutch psychiatric catchment area, by Lange et al.

Authors:  Tanya T Nguyen; Dilip V Jeste
Journal:  Schizophr Res       Date:  2019-08-01       Impact factor: 4.939

9.  Symptomatic remission in a multiracial urban population of older adults with schizophrenia.

Authors:  Azziza Bankole; Carl I Cohen; Ipsit Vahia; Shilpa Diwan; Nikhil Palekar; Pia Reyes; Mamta Sapra; Paul M Ramirez
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

10.  Treating older adults with schizophrenia: challenges and opportunities.

Authors:  Dilip V Jeste; Jeanne E Maglione
Journal:  Schizophr Bull       Date:  2013-04-03       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.